Cat. #153442
Anti-VHL [LIZ167C]
Cat. #: 153442
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: VHL
Class: Monoclonal
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Keith Willison
Institute: The Institute of Cancer Research
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-VHL [LIZ167C]
- Alternate name: von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase
- Clone: LIZ/1/67c
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Cell signalling pathway: VHL
- Description: VHL is Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. It seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. It is involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases.
Target Details
- Target: VHL
- Target background: VHL is Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. It seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. It is involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases.
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
